According to MBS’ press release, the BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA). The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range. Read full story
Related Posts
On the Record: Startup aims to turn scientific researchers into ‘deep-tech’ entrepreneurs
Justin Hafner, founder and former CEO of digital health startup Kinotek, aims to make an even bigger splash in the startup world...
Skincare startup funds UMaine scholarship to spark innovation
Marin Skincare, known for its Lobster Lotion product, partnered with the University of Maine to create a scholarship to spur innovation and...
Bigelow Lab looks to create ‘blue’ biotechnology businesses and jobs
Bigelow Laboratory for Ocean Sciences, an East Boothbay nonprofit research institute focused on global ocean health, last week launched a program...